• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精神分裂症中的记忆损害:来自精神病理学和药物治疗的观点。

Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy.

作者信息

Stip E

机构信息

Centre de recherche Fernand-Seguin, Hôpital Louis-H Lafontaine, Montreal, Quebec.

出版信息

Can J Psychiatry. 1996 Oct;41(8 Suppl 2):S27-34. doi: 10.1177/070674379604100822.

DOI:10.1177/070674379604100822
PMID:8899248
Abstract

OBJECTIVE

To describe the concept of memory impairment in schizophrenia and the clinical implications of this concept in terms of patient assessment and neuroleptic drug use.

METHOD

Narrative literature review.

RESULTS

Individuals suffering from schizophrenia normally exhibit some degree of memory impairment. Recent work in psychopathology indicates that the impairment is comprehensive, involving the sensory, short-term, and long-term memory stores. Memory impairment appears to be a primary symptom of the disease, and its underlying causes are likely organic. A number of medications, however (for example, traditional neuroleptics and drugs that have pronounced anticholinergic activity), may cause or exacerbate impairment. In particular, anticholinergic agents used to treat extrapyramidal symptoms, a common complication of neuroleptic drugs, appear to have a deleterious effect on memory.

CONCLUSIONS

Memory impairment is an important consideration in the clinical assessment and management of patients with schizophrenia. The use of atypical antipsychotics like risperidone appears to have no impact on memory function; because risperidone is associated with a low incidence of extrapyramidal side effects, it can obviate the need for anticholinergic medications-thus offering greater hope of nondebilitative intervention. The advent of medications that are safer (on cognition) could also lead to generally better outcomes by facilitating compliance with drug regimens and rehabilitation programs.

摘要

目的

描述精神分裂症中记忆损害的概念,以及该概念在患者评估和抗精神病药物使用方面的临床意义。

方法

叙述性文献综述。

结果

精神分裂症患者通常表现出一定程度的记忆损害。精神病理学的最新研究表明,这种损害是全面的,涉及感觉记忆、短期记忆和长期记忆存储。记忆损害似乎是该疾病的主要症状,其潜在原因可能是器质性的。然而,一些药物(例如传统抗精神病药物和具有明显抗胆碱能活性的药物)可能会导致或加重记忆损害。特别是,用于治疗锥体外系症状(抗精神病药物的常见并发症)的抗胆碱能药物似乎对记忆有有害影响。

结论

记忆损害是精神分裂症患者临床评估和管理中的一个重要考虑因素。使用利培酮等非典型抗精神病药物似乎对记忆功能没有影响;由于利培酮与锥体外系副作用的发生率较低相关,因此可以避免使用抗胆碱能药物——从而为非致残性干预带来更大希望。安全性更高(对认知功能而言)的药物的出现,也可能通过促进患者对药物治疗方案和康复计划的依从性,带来总体上更好的治疗效果。

相似文献

1
Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy.精神分裂症中的记忆损害:来自精神病理学和药物治疗的观点。
Can J Psychiatry. 1996 Oct;41(8 Suppl 2):S27-34. doi: 10.1177/070674379604100822.
2
Donepezil for memory dysfunction in schizophrenia.多奈哌齐用于治疗精神分裂症的记忆功能障碍。
J Psychopharmacol. 2002 Sep;16(3):267-70. doi: 10.1177/026988110201600313.
3
Discriminant cognitive factors in responder and non-responder patients with schizophrenia.
Eur Psychiatry. 1999 Dec;14(8):442-50. doi: 10.1016/s0924-9338(99)00223-0.
4
Two new atypical antipsychotics: advantages and disadvantages.两种新型非典型抗精神病药物:优缺点
S D J Med. 1998 Aug;51(8):285-6.
5
The effect of risperidone on cognition in patients with schizophrenia.利培酮对精神分裂症患者认知功能的影响
Can J Psychiatry. 1996 Oct;41(8 Suppl 2):S35-40. doi: 10.1177/070674379604100802.
6
The value of atypical antipsychotics in the treatment of schizophrenia.非典型抗精神病药物在精神分裂症治疗中的价值。
Manag Care. 2002 Jul;11(7 Suppl):8-12; discussion 12-3.
7
[Effect of side-effects and complications caused by atypical neuroleptics on the effectiveness of therapy in patients with schizophrenia].
Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(3):48-55.
8
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.糖尿病与使用非典型抗精神病药物治疗精神分裂症之间的关联。
Am J Psychiatry. 2002 Apr;159(4):561-6. doi: 10.1176/appi.ajp.159.4.561.
9
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.精神分裂症的疗效评估:非典型抗精神病药物之间的差异。临床试验评估协作工作组。
J Clin Psychiatry. 1998;59 Suppl 12:3-9.
10
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.奥氮平与其他抗精神病药物在实际门诊环境中的比较:欧洲精神分裂症门诊健康结局研究的六个月耐受性结果
Acta Psychiatr Scand. 2005 Mar;111(3):232-43. doi: 10.1111/j.1600-0447.2004.00451.x.

引用本文的文献

1
Cross-cultural differences through subjective cognition: illustration in translatology with the SSTIC-E in the UAE.跨文化差异的主观认知:以阿联酋的SSTIC-E为例在翻译学中的阐释
Front Psychol. 2024 Mar 7;15:1125990. doi: 10.3389/fpsyg.2024.1125990. eCollection 2024.
2
Usability of the Experience Sampling Method in Specialized Mental Health Care: Pilot Evaluation Study.经验抽样法在专业精神卫生保健中的可用性:试点评估研究。
JMIR Form Res. 2023 Nov 21;7:e48821. doi: 10.2196/48821.
3
Subjective cognitive complaints in first episode psychosis: A focused follow-up on sex effect and alcohol usage.
首发精神病中的主观认知主诉:关于性别效应和饮酒情况的重点随访
Schizophr Res Cogn. 2022 Aug 18;30:100267. doi: 10.1016/j.scog.2022.100267. eCollection 2022 Dec.
4
Dynamic Functional Connectivity Strength Within Different Frequency-Band in Schizophrenia.精神分裂症不同频段内的动态功能连接强度
Front Psychiatry. 2020 Feb 12;10:995. doi: 10.3389/fpsyt.2019.00995. eCollection 2019.
5
Slow Progression of Cognitive Dysfunction of Alzheimer's Disease in Sexagenarian Women with Schizophrenia.老年女性精神分裂症患者阿尔茨海默病认知功能障碍的缓慢进展
Case Rep Psychiatry. 2015;2015:968598. doi: 10.1155/2015/968598. Epub 2015 Jul 12.
6
Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.精神分裂症低谷氨酸能模型中的尼古丁与烟碱系统
Neurotox Res. 2007 Dec;12(4):233-46. doi: 10.1007/BF03033907.
7
Memory tests in first-degree adult relatives of schizophrenic patients: a meta-analysis.精神分裂症患者一级成年亲属的记忆测试:一项荟萃分析。
Schizophr Res. 2006 Jan 31;81(2-3):217-26. doi: 10.1016/j.schres.2005.09.005. Epub 2005 Oct 21.
8
The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats.代谢型谷氨酸受体5拮抗剂2-甲基-6-(苯乙炔基)吡啶(MPEP)增强了大鼠中苯环己哌啶诱导的认知缺陷。
Psychopharmacology (Berl). 2004 Sep;175(3):310-8. doi: 10.1007/s00213-004-1827-5.